Frontline Ramucirumab Does Not Improve OS in Gastric Cancer OncLive Adding ramucirumab (Cyramza) to cisplatin and capecitabine or 5-FU (5-fluorouracil) in the frontline setting did not improve overall survival (OS) in patients with HER2-negative metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma...
F-fluorodeoxyglucose uptake predicts MET expression in lung adenocarcinoma - Dove Medical Press
What our clients and candidates are saying about us: I chose you over all the MONSTER recruiters because your clients are the ones I’m looking for...and your personal professionalism throughout December was like nothing I've ever experienced. - Kyle
The #1 Resource for professionals in the Pharmaceutical Advertising, Medical Communications, Healthcare Public Relations, Pharmaceutical Industry, and Biotechnology fields since 1988.